ACUTE GRAFT VERSUS HOST DESEASE
MEDICAL CODING CLASSES IN KOCHI.
Transorze Solutions offers 100% job assurance for trainees to get employed in top companies in your hometown
Medical Coding is converting a diagnosis or symptoms, procedures, and drugs into codes and Medical billing is billing insurance companies and patients for procedures and office visits. Their work is submitted to insurance companies for payment purposes, data collection, research, billing and quality improvement purposes.
ACUTE GRAFT VERSUS HOST DESEASE
Acute graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplant and is a reaction of donor immune cells against host tissues. Activated donor T cells damage host epithelial cells after an inflammatory cascade that begins with the preparative regimen.Graft versus host disease (GVHD) is an immune-mediated condition resulting from a complex interaction between donor and recipient adaptive immunity. Acute GVHD describes a distinctive syndrome of dermatitis (see the image below), hepatitis, and enteritis developing within 100 days after allogeneic hematopoietic cell transplantation (HCT). Chronic GVHD describes a more diverse syndrome developing after day 100. In addition to allogeneic HCT, procedures associated with high risk of GVHD include transplantation of solid organs containing lymphoid tissue and transfusion of unirradiated blood products.
TYPESIn the clinical setting, graft-versus-host-disease is divided into acute and chronic forms, and scored or graded on the basis of the tissue affected and the severity of the reaction.
In the classical sense, acute graft-versus-host-disease is characterized by selective damage to the liver, skin (rash), mucosa, and the gastrointestinal tract. Newer research indicates that other graft-versus-host-disease target organs include the immune system (the hematopoietic system, e.g., the bone marrow and the thymus) itself, and the lungs in the form of immune-mediated pneumonitis. Biomarkers can be used to identify specific causes of GvHD, such as elafin in the skin. Chronic graft-versus-host-disease also attacks the above organs, but over its long-term course can also cause damage to the connective tissue and exocrine glands.
Mucosal damage to the vagina can result in severe pain and scarring, and appears in both acute and chronic GvHD. This can result in an inability to have sexual intercourse.
In the clinical setting, graft-versus-host-disease is divided into acute and chronic forms, and scored or graded on the basis of the tissue affected and the severity of the reaction.
In the classical sense, acute graft-versus-host-disease is characterized by selective damage to the liver, skin (rash), mucosa, and the gastrointestinal tract. Newer research indicates that other graft-versus-host-disease target organs include the immune system (the hematopoietic system, e.g., the bone marrow and the thymus) itself, and the lungs in the form of immune-mediated pneumonitis. Biomarkers can be used to identify specific causes of GvHD, such as elafin in the skin. Chronic graft-versus-host-disease also attacks the above organs, but over its long-term course can also cause damage to the connective tissue and exocrine glands.
Mucosal damage to the vagina can result in severe pain and scarring, and appears in both acute and chronic GvHD. This can result in an inability to have sexual intercourse.
Acute
The acute or fulminant form of the disease (aGvHD) is normally observed within the first 10 to 100 days post-transplant,and is a major challenge to transplants owing to associated morbidity and mortality. About one-third to one-half of allogeneic transplant recipients will develop acute GvHD. It's less common in younger patients and in those with closer human leukocyte antigens (HLA) matches between donor and the patient.
The first signs are usually a rash, burning, and redness of the skin on the palms and soles. This can spread over the entire body. Other symptoms can include Nausea, vomiting, stomach cramps, diarrhea (watery and sometimes bloody), loss of appetite, jaundice, abdominal pain, and weight loss.
Acute GvHD of the GI tract can result in severe intestinal inflammation, sloughing of the mucosal membrane, severe diarrhea, abdominal pain, nausea, and vomiting. This is typically diagnosed via intestinal biopsy. Liver GvHD is measured by the bilirubin level in acute patients. Skin GvHD results in a diffuse red maculopapular rash,sometimes in a lacy pattern.
Acute GvHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of 1 to a high of 4. Patients with grade IV GvHD usually have a poor prognosis. If the GvHD is severe and requires intense immunosuppression involving steroids and additional agents to get under control, the patient may develop severe infections as a result of the immunosuppression and may die of infection. However, a 2016 study found that the prognosis for patients with grade IV GvHD has improved in recent years.
The acute or fulminant form of the disease (aGvHD) is normally observed within the first 10 to 100 days post-transplant,and is a major challenge to transplants owing to associated morbidity and mortality. About one-third to one-half of allogeneic transplant recipients will develop acute GvHD. It's less common in younger patients and in those with closer human leukocyte antigens (HLA) matches between donor and the patient.
The first signs are usually a rash, burning, and redness of the skin on the palms and soles. This can spread over the entire body. Other symptoms can include Nausea, vomiting, stomach cramps, diarrhea (watery and sometimes bloody), loss of appetite, jaundice, abdominal pain, and weight loss.
Acute GvHD of the GI tract can result in severe intestinal inflammation, sloughing of the mucosal membrane, severe diarrhea, abdominal pain, nausea, and vomiting. This is typically diagnosed via intestinal biopsy. Liver GvHD is measured by the bilirubin level in acute patients. Skin GvHD results in a diffuse red maculopapular rash,sometimes in a lacy pattern.
Acute GvHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of 1 to a high of 4. Patients with grade IV GvHD usually have a poor prognosis. If the GvHD is severe and requires intense immunosuppression involving steroids and additional agents to get under control, the patient may develop severe infections as a result of the immunosuppression and may die of infection. However, a 2016 study found that the prognosis for patients with grade IV GvHD has improved in recent years.
Chronic
The chronic form of graft-versus-host-disease (cGvHD) normally begins 90 to 600 days post-transplant. The appearance of moderate to severe cases of cGVHD adversely influences long-term survival.
The first symptom of cGvHD is commonly a rash on the palms of the hands or the soles of the feet, and the rash can spread and is usually itchy and dry. In severe cases, the skin may blister and peel, like a bad sunburn. A fever may also develop. Other symptoms of chronic GVHD can include
- Decreased appetite
- Diarrhea
- Abdominal (belly) cramps
- Weight loss
- Yellowing of the skin and eyes (jaundice)
- Enlarged liver
- Bloated abdomen (belly)
- Pain in the upper right part of the abdomen (belly)
- Increased levels of liver enzymes in the blood (seen on blood tests)
- Skin that feels tight
- Dry, burning eyes
- Dryness or painful sores in the mouth
- Burning sensations when eating acidic foods
- Bacterial infections
- Blockages in the smaller airways of the lungs
In the oral cavity, chronic graft-versus-host-disease manifests as lichen planus with a higher risk of malignant transformation to oral squamous cell carcinoma in comparison to the classical oral lichen planus. Graft-versus-host-disease-associated oral cancer may have more aggressive behavior with poorer prognosis, when compared to oral cancer in non-hematopoietic stem cell transplantation patients.
Healthcare providers use medications to suppress the immune system or anti-inflammatory medications such as steroids to treat GVHD. The choice will depend on the whether the condition is acute or chronic.
People with GVHD may require treatment for up to a year and beyond depending on how they respond to therapy.
Acute GVHD is typically treated with a class of medication called glucocorticoids (steroids) and cyclosporine (immunosuppressive drugs).
Additional medications that have either been newly approved or are undergoing evaluation in clinical trials include:
- antithymocyte globulin (rabbit ATG; Thymoglobulin)
- denileukin diftitox (Ontak)
- monoclonal antibodies, such as daclizumab (Zenapax), infliximab (Remicade), or, more rarely, alemtuzumab (Campath)
- mycophenolate mofetil (CellCept)
- sirolimus (Rapamune)
- tacrolimus (Prograf)
- oral non-absorbable corticosteroids, such as budesonide or beclomethasone dipropionate
- intra-arterial corticosteroids
- pentostatin (Nipent)
Another potential form of treatment is extracorporeal photopheresis, a procedure under study that removes, treats, and reinfuses the patient’s blood. Infusions of mesenchymal stem cells are currently under trial.
Chronic GVHD is typically treated with a class of steroids called corticosteroids, and possibly cyclosporine. Other medications are available if the GVHD is not responding to traditional therapy. These include:
- daclizumab (Zenapax)
- etanercept (Enbrel)
- infliximab (Remicade)
- mycophenolate mofetil (CellCept)
- pentostatin (Nipent)
- tacrolimus (Prograf)
- thalidomide (Thalomid)
- imatinibmesylate (Gleevec) for some skin changes
The chronic form of graft-versus-host-disease (cGvHD) normally begins 90 to 600 days post-transplant. The appearance of moderate to severe cases of cGVHD adversely influences long-term survival.
The first symptom of cGvHD is commonly a rash on the palms of the hands or the soles of the feet, and the rash can spread and is usually itchy and dry. In severe cases, the skin may blister and peel, like a bad sunburn. A fever may also develop. Other symptoms of chronic GVHD can include
- Decreased appetite
- Diarrhea
- Abdominal (belly) cramps
- Weight loss
- Yellowing of the skin and eyes (jaundice)
- Enlarged liver
- Bloated abdomen (belly)
- Pain in the upper right part of the abdomen (belly)
- Increased levels of liver enzymes in the blood (seen on blood tests)
- Skin that feels tight
- Dry, burning eyes
- Dryness or painful sores in the mouth
- Burning sensations when eating acidic foods
- Bacterial infections
- Blockages in the smaller airways of the lungs
In the oral cavity, chronic graft-versus-host-disease manifests as lichen planus with a higher risk of malignant transformation to oral squamous cell carcinoma in comparison to the classical oral lichen planus. Graft-versus-host-disease-associated oral cancer may have more aggressive behavior with poorer prognosis, when compared to oral cancer in non-hematopoietic stem cell transplantation patients.
 |
Healthcare providers use medications to suppress the immune system or anti-inflammatory medications such as steroids to treat GVHD. The choice will depend on the whether the condition is acute or chronic.
People with GVHD may require treatment for up to a year and beyond depending on how they respond to therapy.
Acute GVHD is typically treated with a class of medication called glucocorticoids (steroids) and cyclosporine (immunosuppressive drugs).
Additional medications that have either been newly approved or are undergoing evaluation in clinical trials include:
- antithymocyte globulin (rabbit ATG; Thymoglobulin)
- denileukin diftitox (Ontak)
- monoclonal antibodies, such as daclizumab (Zenapax), infliximab (Remicade), or, more rarely, alemtuzumab (Campath)
- mycophenolate mofetil (CellCept)
- sirolimus (Rapamune)
- tacrolimus (Prograf)
- oral non-absorbable corticosteroids, such as budesonide or beclomethasone dipropionate
- intra-arterial corticosteroids
- pentostatin (Nipent)
Another potential form of treatment is extracorporeal photopheresis, a procedure under study that removes, treats, and reinfuses the patient’s blood. Infusions of mesenchymal stem cells are currently under trial.
Chronic GVHD is typically treated with a class of steroids called corticosteroids, and possibly cyclosporine. Other medications are available if the GVHD is not responding to traditional therapy. These include:
- daclizumab (Zenapax)
- etanercept (Enbrel)
- infliximab (Remicade)
- mycophenolate mofetil (CellCept)
- pentostatin (Nipent)
- tacrolimus (Prograf)
- thalidomide (Thalomid)
- imatinibmesylate (Gleevec) for some skin changes
Comments
Post a Comment